Human Follitropin Alfa, Recombinant shortage — EU supply status & alternatives

Human Follitropin Alfa, Recombinant

—

In supply · Australia

Bemfola

In supply · 🇦🇺 Australia · short in🌐 EU🇧🇪 BE🌐 IS

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Brand names
Active ingredient (INN)	Human Follitropin Alfa, Recombinant

Therapeutic category	Auto-created by Federal Agency for Medicines and Health Products — PharmaStatus scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Recalls official enforcement reports

🌐

Silgard

Merck Sharp Dohme Ltd · Feb 2019

Class Unifieddetails ↗

🇨🇦

Human placenta products for consumption not authorized in Canada

Communications and Public Affairs Branch · Nov 2018

Class ?details ↗

🇺🇸

Human Chorionic Gonadotropic (Hcg) Sublingual Drops

Life Science Pharmacy Inc · June 2015

Class IIdetails ↗

Verified timeline regulator events

🌐 2 July 2026

medium reported

🌐 21 May 2026

Shortage resolved

🇧🇪 13 May 2026

medium reported

🌐 15 Apr 2026

Shortage resolved

🇧🇪 25 Mar 2026

medium reported

🌐 24 Feb 2026

Shortage resolved

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.